118 related articles for article (PubMed ID: 38689576)
21. The effect of Oncotype DX
Rabie MA; Rankin A; Burger A; Youssef M
Ann R Coll Surg Engl; 2019 Nov; 101(8):596-601. PubMed ID: 31219316
[TBL] [Abstract][Full Text] [Related]
22. The Oncotype DX Recurrence Score's Impact on the Management of Oestrogen-Positive/Human Epidermal Growth Factor Receptor 2-Negative, Low-Burden Axillary Status Breast Cancer (REHAB Study): Results of a Single Centre.
Saad Abdalla Al-Zawi A; Yin SL; Mahmood B; Jalil A; Aladili Z
Cureus; 2022 Jul; 14(7):e27341. PubMed ID: 36042999
[TBL] [Abstract][Full Text] [Related]
23. Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
Orucevic A; Bell JL; McNabb AP; Heidel RE
Breast Cancer Res Treat; 2017 May; 163(1):51-61. PubMed ID: 28243897
[TBL] [Abstract][Full Text] [Related]
24. Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia.
Collin LJ; Yan M; Jiang R; Ward KC; Crawford B; Torres MA; Gogineni K; Subhedar PD; Puvanesarajah S; Gaudet MM; McCullough LE
NPJ Breast Cancer; 2019; 5():32. PubMed ID: 31583272
[TBL] [Abstract][Full Text] [Related]
25. The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment.
Iles K; Roberson ML; Spanheimer P; Gallagher K; Ollila DW; Strassle PD; Downs-Canner S
NPJ Breast Cancer; 2022 Mar; 8(1):27. PubMed ID: 35232996
[TBL] [Abstract][Full Text] [Related]
26. The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer.
Rizki H; Hillyar C; Abbassi O; Miles-Dua S
Cureus; 2020 Mar; 12(3):e7269. PubMed ID: 32195072
[TBL] [Abstract][Full Text] [Related]
27. Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.
Jahn B; Rochau U; Kurzthaler C; Hubalek M; Miksad R; Sroczynski G; Paulden M; Bundo M; Stenehjem D; Brixner D; Krahn M; Siebert U
BMC Cancer; 2017 Oct; 17(1):685. PubMed ID: 29037213
[TBL] [Abstract][Full Text] [Related]
28. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort.
Ademuyiwa FO; Miller A; O'Connor T; Edge SB; Thorat MA; Sledge GW; Levine E; Badve S
Breast Cancer Res Treat; 2011 Apr; 126(3):797-802. PubMed ID: 21197567
[TBL] [Abstract][Full Text] [Related]
29. Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016.
Schwedhelm TM; Rees JR; Onega T; Zipkin RJ; Schaefer A; Celaya MO; Moen EL
BMC Cancer; 2020 Sep; 20(1):847. PubMed ID: 32883270
[TBL] [Abstract][Full Text] [Related]
30. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
[TBL] [Abstract][Full Text] [Related]
31. Surgeon and medical oncologist peer network effects on the uptake of the 21-gene breast cancer recurrence score assay.
Zipkin R; Schaefer A; Chamberlin M; Onega T; O'Malley AJ; Moen EL
Cancer Med; 2021 Feb; 10(4):1253-1263. PubMed ID: 33455068
[TBL] [Abstract][Full Text] [Related]
32. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
Harowicz MR; Robinson TJ; Dinan MA; Saha A; Marks JR; Marcom PK; Mazurowski MA
Breast Cancer Res Treat; 2017 Feb; 162(1):1-10. PubMed ID: 28064383
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2- Breast Cancer.
Song R; Lee DE; Lee EG; Lee S; Kang HS; Han JH; Lee KS; Sim SH; Chae H; Kwon Y; Woo J; Jung SY
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760420
[TBL] [Abstract][Full Text] [Related]
34. Impact of 21-Gene Expression Assay on Clinical Outcomes in Node-Negative ≤ T1b Breast Cancer.
Pomponio M; Keele L; Hilt E; Burkbauer L; Goldbach M; Nazarian S; Fox K; Tchou J
Ann Surg Oncol; 2020 May; 27(5):1671-1678. PubMed ID: 31686348
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study.
Oliveira LJC; Megid TBC; Rosa DD; Magliano CADS; Assad DX; Argolo DF; Sanches SM; Testa L; Bines J; Kaliks R; Caleffi M; de Melo Gagliato D; Sahade M; Barroso-Sousa R; Corrêa TS; Shimada AK; Batista DN; Musse Gomes D; Cesca MG; Gaudêncio D; Moura LMA; de Araújo JAP; Katz A; Mano MS
Ther Adv Med Oncol; 2022; 14():17588359221141760. PubMed ID: 36601632
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological correlates, oncological impact, and validation of Oncotype DX™ in a European Tertiary Referral Centre.
Davey MG; Ryan ÉJ; Abd Elwahab S; Elliott JA; McAnena PF; Sweeney KJ; Malone CM; McLaughlin R; Barry MK; Keane MM; Lowery AJ; Kerin MJ
Breast J; 2021 Jun; 27(6):521-528. PubMed ID: 33709552
[TBL] [Abstract][Full Text] [Related]
37. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
38. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
[TBL] [Abstract][Full Text] [Related]
39. A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands.
Simons MJHG; Machielsen PM; Spoorendonk JA; Ignacio T; Drost PB; Jacobs T; de Jongh FE
J Med Econ; 2024; 27(1):445-454. PubMed ID: 38436289
[TBL] [Abstract][Full Text] [Related]
40. Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.
Neely C; You S; Mendoza PM; Aneja R; Sahin AA; Li X
Breast J; 2018 Nov; 24(6):889-893. PubMed ID: 30230095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
